Meanwhile, other researchers have shown that IGF2BP3 inhibits CD8+ T cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer (46). Here, IGF2BP3 is linked to non-small cell lung carcinoma.